# Somatic structural variation signatures in pediatric brain tumors

3

4 Yang Yang<sup>1</sup>, Lixing Yang<sup>1,2,3,\*\*</sup>

- 5 1. Ben May Department for Cancer Research, University of Chicago, Chicago, IL, USA
- 6 2. Department of Human Genetics, University of Chicago, Chicago, IL, USA
- 7 3. University of Chicago Comprehensive Cancer Center, Chicago, IL, USA
- 8 Correspondence: lixingyang@uchicago.edu

#### 9 Summary

- 10 Brain cancer is the leading cause of cancer-related death in children. Somatic structural
- 11 variations (SVs), large scale alterations in DNA, remain poorly understood in pediatric brain
- 12 tumors. Here, we detect a total of 13,199 high confidence somatic SVs in 744 whole-genome-
- 13 sequenced pediatric brain tumors from Pediatric Brain Tumor Atlas. The somatic SV
- 14 occurrences have tremendous diversity among the cohort and across different tumor types. We
- 15 decompose mutational signatures of clustered complex SVs, non-clustered complex SVs, and
- simple SVs separately to infer the mutational mechanisms of SV formation. Our finding of many
- 17 tumor types carrying unique sets of SV signatures suggests that distinct molecular mechanisms
- 18 are active in different tumor types to shape genome instability. The patterns of somatic SV
- 19 signatures in pediatric brain tumors are substantially different from those in adult cancers. The
- 20 convergence of multiple signatures to alter several major cancer driver genes suggesting the
- 21 functional importance of somatic SVs in disease progression.
- 22

#### 23 Keywords

24 Genome instability, genomic rearrangement, chromothripsis, gene fusion

#### 25 Introduction

- 26 Brain and central nervous system cancers are the most prevalent solid tumors in children under
- 19 and are the leading cause of cancer-related death among children (Ostrom et al., 2015). There
- are more than 100 types of pediatric brain tumors, which differ markedly from adult brain tumors
- 29 (Louis et al., 2007). Although the 5-year survival rate of pediatric brain tumors is 75%, the
- 30 survivors often suffer over their lifetimes from both the disease and the side effects of treatments.
- 31 Therefore, there is an urgent need to better understand the disease mechanisms and to develop
- new therapeutic strategies in order to further increase survival and improve the quality of life for
- 33 patients and their families.
- 34 Genetic alterations in cancer include single nucleotide variants (SNVs), copy number variants
- 35 (CNVs), and structural variations (SVs). Pediatric brain tumors have few somatic SNVs, but
- carry more somatic SVs than other pediatric cancers (Gröbner et al., 2018). SVs are large scale
- 37 structural changes of DNA such as deletions, tandem duplications, inversions, translocations, and
- 38 some can be quite complex. For example, chromothripsis refers to a single catastrophic event
- resulting in numerous SVs through one cell cycle (Maciejowski et al., 2015; Stephens et al.,
- 40 2011; Zhang et al., 2015). Understanding the mechanisms behind these alterations not only can
- 41 improve our knowledge of disease biology, but also can reveal therapeutic opportunities. For
- 42 instance, translocations at the immunoglobulin gene locus in B cell lymphoma are caused by
- 43 aberrant V(D)J recombination (Alt et al., 2013; Hakim et al., 2012) and often result in activations
- of *MYC* and *BCL2* oncogenes (Bakhshi et al., 1985; Gostissa et al., 2009). Furthermore, breast
- and ovarian cancer patients carrying *BRCA1* and *BRCA2* mutations have deficiency in DNA
- double strand break repair and elevated level of somatic SVs in their tumors (Lee et al., 2016;
- 47 Nik-Zainal et al., 2016). Patients with BRCA deficiency can be effectively treated by PARP
- 48 inhibitors (Farmer et al., 2005; Fong et al., 2009). Mutational signatures have been widely used
- to study the molecular mechanisms of SNVs (Alexandrov et al., 2013, 2020; Degasperi et al.,
- 50 2022), CNVs (Drews et al., 2022; Steele et al., 2022), SVs (Li et al., 2020) and complex SVs
- 51 (Bao et al., 2022) in adult cancers. However, comprehensive studies of somatic SV signatures in
- 52 pediatric brain tumors are still lacking. A recent study of SV signatures in pediatric high-grade
- 53 glioma has revealed that histone genes, *TP53*, *CDKN2A*, and *RB1* aberrations are associated with
- 54 complex SVs (Dubois et al., 2022). However, whether other types of pediatric brain tumors
- 55 harbor similar SV signatures remains unclear.
- 56 Here, we decompose complex and simple SV signatures from 744 pediatric brain tumors. We
- 57 find tremendous heterogeneity in SV occurrences and SV signatures across tumor types. We also
- report that somatic SVs are frequent cancer drivers in pediatric brain tumors.
- 59
- 60

#### 61 **Results and Discussion**

#### 62 High confidence somatic SVs in pediatric brain tumors

- 63 Pediatric Brain Tumor Atlas (PBTA) has collected more than 1,000 pediatric brain tumors across
- 64 more than 30 types. There were 744 samples in PBTA with whole-genome sequencing data after
- removing non-tumorous lesions, non-brain cancer, and non-primary cancer samples (Table S1).
- 66 We focused on tumor types with at least 10 samples including: 220 low-grade astrocytic tumors
- 67 (LGATs), 97 medulloblastomas, 71 ependymomas, 70 high-grade gliomas (HGGs), 44
- 68 gangliogliomas, 38 craniopharyngiomas, 27 atypical teratoid rhabdoid tumors (ATRTs), 23
- 69 meningiomas, 23 dysembryoplastic neuroepithelial tumors (DNETs), 17 non-meningothelial
- mesenchymal tumors, 13 schwannomas, 13 germ cell tumors, 13 neurofibromas, and 12 choroid
- 71 plexus papillomas. Tumor types with less than 10 samples were all classified as "Others".
- A previous study used Manta (Chen et al., 2016) to detect somatic SVs in the PBTA cohort to
- study the effects of SVs on gene expression (Zhang et al., 2021). However, the quality of
- variants called by a single algorithm is always not ideal (Campbell et al., 2020). In order to
- 75 produce high confidence somatic SVs, we integrated three SV calling algorithms: Meerkat (Yang
- ret al., 2013), Manta and Delly (Rausch et al., 2012a). Caller-specific SVs were discarded, and the
- somatic SVs detected by more than one algorithm were considered as high confidence. Meerkat,
- Manta and Delly detected 14,423, 55,934 and 9,475 somatic SVs in the 744 samples,
- respectively (Figure S1A). Since tumor DNA was not available, the SV quality could not be
- 80 directly measured. Instead, we used CNV breakpoints detected by read depth approach to assess
- the quality of SVs, since a portion of somatic SVs change DNA copy numbers. We found SVs
- detected by only one algorithm were not well supported by CNVs (Figure S1B), which suggested
- 83 that caller-specific SVs had poorer quality. SVs detected by Manta with fewer read pair and split
- read support were particularly of poor quality (Figure S1C). SVs detected by more than one
- algorithm were better supported by CNVs (Figure S1B), which suggested that they were of high
- quality. We also removed deletions that resided at exon-intron boundaries which were likely
- caused by cDNA contamination (Campbell et al., 2020). As a result, a total of 13,199 high
- confidence SVs were detected from 744 pediatric brain tumors with a median of 3 SVs per
- sample. In each type of pediatric brain tumor, the number of somatic SVs per sample varied bynearly three orders of magnitude (Figure 1A). There was also considerable heterogeneity across
- 91 tumor types. HGGs were most abundant in somatic SVs followed by meningiomas and
- 92 medulloblastomas, whereas choroid plexus papillomas had no SV at all (Figure 1A). Although
- 93 most LGATs, ependymomas, gangliogliomas, and neurofibromas had very few SVs, a small
- fraction of them had very unstable genomes with more than 100 SVs (Figure 1A).
- 95

# 96 Complex SVs in pediatric brain tumors

- 97 A non-negative-matrix-factorization-(NMF)-based approach has been very effective in
- 98 decomposing mutational signatures for somatic SNVs (Alexandrov et al., 2013, 2020; Degasperi
- et al., 2022) and CNVs (Drews et al., 2022; Steele et al., 2022). Several studies, including the
- 100 recent SV signature study in pediatric high-grade glioma (Dubois et al., 2022), also used this

101 approach to extract SV signatures by combining both complex SVs and simple SVs (Li et al., 102 2020). Meaningful signatures can be reliably detected if DNA damage and repair mechanisms 103 generate variants independently and repeatedly in cancer genomes. However, it is wellestablished that chromothripsis events occur as one-time events and the numbers of SVs vary 104 extensively (Maciejowski et al., 2015; Shoshani et al., 2020; Zhang et al., 2015). Furthermore, 105 106 multiple molecular mechanisms can lead to chromothripsis. For example, lagging chromosomes trapped in micronuclei during mitosis can shatter into many pieces and some fragments can be 107 ligated together as chromothripsis events (Zhang et al., 2015). Dicentric chromosomes can form 108 chromatin bridges during cell division, shatter into pieces, and also produce chromothripsis 109 (Maciejowski et al., 2015). NMF-based SV signature decomposition cannot differentiate these 110 mechanisms. To better deduce SV signatures in pediatric brain tumors, we studied clustered 111 complex SVs, non-clustered complex SVs and simple SVs separately. Clustered complex SVs 112 are those with breakpoints enriched in certain genomic regions including chromothripsis. 113 Circular extrachromosomal DNA (ecDNA) with many SV breakpoints is also a clustered 114 complex SV (Bao et al., 2022). We recently developed Starfish, a clustering-based approach, to 115 116 infer clustered complex SV signatures based on their SV and CNV patterns (Bao et al., 2022). We reported six clustered complex SV signatures using nearly 2,500 adult tumors including 117 micronuclei-induced chromothripsis, chromatin-bridge-induced chromothripsis, as well as 118 ecDNA. There are three other signatures that cannot be linked to biological processes, namely 119 "Large loss", "Large gain" and "Hourglass". Non-clustered complex SVs are complex SVs with 120 scattered breakpoints including chromoplexy and cycle of templated insertions (Li et al., 2020). 121 122 Chromoplexy events are likely to form through repair of multiple co-occurring DNA double 123 strand breaks similar to reciprocal translocations (Baca et al., 2013; Berger et al., 2011), whereas templated insertions may reflect replication-based mechanisms (Li et al., 2020; Yang et al., 124 2013; Zhang et al., 2009). After detecting clustered and non-clustered complex SVs, the 125 126 remainder of SVs were classified as simple SVs, which include deletions, tandem duplications, balanced/unbalanced/foldback inversions, and balanced/unbalanced translocations. 127 128 Among the 13,199 SVs in 744 pediatric brain tumors, 7,601 (57.6%) were clustered complex SVs that belonged to 146 individual complex events, 2,377 (18.0%) were non-clustered complex 129 SVs that belonged to 346 events, and 3,221 (24.4%) were simple SVs (Table S2). Out of the 744 130 tumors, 108 (14.5%) and 150 (20.2%) carried clustered and non-clustered complex SVs 131 respectively, whereas 552 (74.2%) did not have any complex SVs. The high numbers of SVs in 132 tumors with very unstable genomes (>100 SVs) were mainly due to their abundance of complex 133 SVs (Figure 1A and Figure S2). HGGs were most abundant in complex SVs, whereas DNETs 134 135 did not carry any complex SVs (Figure 1A). We used Starfish (Bao et al., 2022) to classify clustered complex SV signatures (Table S3) and used junction pattern (Li et al., 2020) to 136 137 determine non-clustered complex SVs. HGGs and medulloblastomas carried almost all complex 138 SV signatures, whereas other tumor types only harbored small numbers of complex SV 139 signatures (Figure 1B). The "ecDNA" (Figure 1C) signature was predominantly found in HGGs; 140 the "Large loss" signature (Figure 1C), characterized by complex SVs with large amount of

- 141 DNA loss, was mainly observed in HGGs and meningiomas; micronuclei-induced
- 142 chromothripsis ("Micronuclei" signature) (Figure 1C) was enriched in mesenchymal tumors and
- 143 ependymomas (Figure 1B). Chromatin-bridge-induced chromothripsis ("Chr bridge" signature)

- 144 (Figure 1C) only occurred in HGGs and neurofibromas (Figure 1B). Hourglass chromothripsis
- 145 events ("Hourglass" signature), complex SVs with a small amount of DNA loss and highly
- 146 concentrated SV breakpoints, were detected in a small number of samples in several tumor types
- 147 (Figure 1B), such as HGGs, meningiomas, medulloblastomas, and ependymomas. Regarding to
- 148 non-clustered complex SVs, chromoplexy was found in many different tumor types and occurred
- in as many as 18.6% (13/70) of HGGs and 17.6% (3/17) of mesenchymal tumors (Figure 1D).
- 150 Cycle of templated insertions was abundant in HGGs (Figure 1D).
- 151 In summary, different types of pediatric brain tumors often carry distinct complex SV signatures.
- 152

#### 153 Simple SVs in pediatric brain tumors

- 154 Next, we used the NMF approach to decompose simple SV signatures; a total of nine signatures
- were extracted (Figure 2A and Table S2). These signatures included deletions smaller than 1kb
- 156 ("Del0"), deletions between 1kb to 5kb ("Del1"), deletions larger than 5kb ("Del2"), tandem
- 157 duplications ("TD"), unbalanced inversions ("Unbal inv"), large intra-chromosomal SVs ("Large
- mixed"), reciprocal inversions and reciprocal translocations ("Recip"), as well as unbalanced
- translocations ("Unbal tra"). Interestingly, large tandem duplications resulting in *KIAA1549*-
- 160 *BRAF* fusions belonged to a stand-alone signature, namely "*BRAF* fusion". HGGs had more
- simple SVs than other tumor types, while a considerable number of samples from various tumor
- types, including LGATs and ependymomas, showed no evidence of simple SVs (Figure 2B).
- 163 Most tumors with simple SVs carried multiple simple SV signatures (Figure 2B), and apparent
- 164 enrichments could be observed. For example, DNETs predominantly carried the "TD" signature;
- schwannomas mainly harbored the "Recip" signature; the "Unbal inv" signature was mainly
- found in HGGs; the "TD" signature was enriched in medulloblastomas; and "Del2" signature
- 167 was abundant in ATRTs; and the "*BRAF* fusion" signature was almost exclusively observed in
- LGATs (Figure 2B). Intriguingly, 102 out of 220 LGATs had *KIAA1549-BRAF* fusions, and among the fusion positive LGATs, 88 had only one SV present in their genomes. The SVs
- producing *KIAA1549-BRAF* fusions were exclusively tandem duplications between 1Mb and
- 171 2.5Mb in size (Figure 2A).
- 172 Taken together, our complex SV and simple SV signature analysis demonstrated that numerous
- mutational mechanisms are active in pediatric brain tumors to induce genome instability, with
- 174 unique molecular mechanisms present in different tumor types.

# 175 **Genomic features associated with SV signatures**

- 176 Somatic SVs are not evenly distributed across the genome (Li et al., 2020). Many factors, such as
- replication timing, GC content, repeat content, and 3D genome organization, have been
- associated with SV breakpoint distribution (Akdemir et al., 2020; Li et al., 2020). Here, we
- surveyed 31 genomic features for their relationships with somatic SVs in pediatric brain tumors
- 180 (Figure 3).
- 181 For clustered complex SV signatures, SV breakpoints of the "ecDNA", "Chr bridge" and "Large
- 182 gain" signatures were significantly enriched in late replicated regions (Figure 3). In contrast, all

183 clustered complex SV signatures in adult cancers were enriched in early replicated regions (Bao

- 184 et al., 2022). In adult cancers, all clustered complex SV signatures were enriched in GC-rich
- regions and near CpG islands (Bao et al., 2022), whereas only the "ecDNA" and "Micronuclei"
- signatures in pediatric brain tumors were enriched in GC-rich regions (Figure 3). SV breakpoints
- 187 of the "Large loss" signature were significantly closer to centromeres than expected in pediatric
- brain tumors (Figure 3), in a pattern opposite to adult cancers (Bao et al., 2022). In adult cancers,
- the "ecDNA" and "Chr bridge" signatures were significantly farther away from telomeres,
- 190 whereas other clustered complex SVs were significantly closer to telomeres (Bao et al., 2022).
- 191 However, all clustered complex SV signatures were significantly closer to telomeres in pediatric
- brain tumors (Figure 3). All clustered complex SV signatures in adult cancers were significantly
- 193 closer to many types of repetitive elements (simple repeats, short tandem repeats and
- transposable elements) (Bao et al., 2022), whereas in pediatric brain tumors, the repetitive
- elements had variable effects. For example, the "Micronuclei" signature in pediatric brain tumors
- 196 were enriched near Alu elements but depleted around L1s (Figure 3). Therefore, the SV
- 197 breakpoint distributions of clustered complex SVs in pediatric brain tumors were quite different
- 198 from those of adult cancers.
- 199 Chromoplexy was proposed to form similar to reciprocal translocations through simultaneous
- ligation of multiple broken chromosomal ends (Baca et al., 2013; Berger et al., 2011). In adult
- 201 cancers, chromoplexy breakpoints and reciprocal translocations shared similar patterns. For
- example, they were both enriched in late replicated regions. In sharp contrast, chromoplexy
- breakpoints in pediatric brain tumors were enriched in early replicated regions while reciprocal
- translocations did not display any bias in replication timing (Figure 3). In addition, chromoplexy
- breakpoints in pediatric brain tumors were also enriched in GC-rich regions and near telomeres,
- 206 while reciprocal translocations were enriched in AT-rich regions and not enriched towards either
- 207 centromeres or telomeres (Figure 3). These results suggested that chromoplexy in pediatric brain
- tumors may form through a different mechanism than reciprocal translocations. Cycle of
- 209 templated insertion breakpoints in pediatric brain tumors had little association with most
- 210 genomic features except for proximity to telomeres (Figure 3).
- 211 Simple SV breakpoint distributions of pediatric brain tumors were also quite distinct from those
- of adult cancers. In adult cancers, deletions were enriched in early replicated regions, and tandem
- duplications and unbalanced translocations were enriched in late replicated regions (Li et al.,
- 214 2020). In contrast, in pediatric brain tumors, smaller deletions ("Del0" and "Del1") were not
- associated with replication timing, large deletions ("Del2") were enriched in late replicated
- regions, and tandem duplications ("TD") as well as unbalanced translocations ("Unbal tra") were
- enriched in early replicated regions (Figure 3). In adult cancers, all deletions regardless of their
- sizes were enriched in AT-rich regions (Li et al., 2020); whereas in pediatric brain tumors, small
- 219 deletions ("Del1") were enriched in GC-rich regions and large deletions ("Del2") were enriched
- 220 in AT-rich regions (Figure 3). In adult cancers, tandem duplications were significantly closer to
- Alu elements (Li et al., 2020); whereas in pediatric brain tumors, tandem duplications ("TD")
- were farther away from L1s, LTR transposons, and DNA transposons (Figure 3). In adult
- 223 cancers, both small and large deletions were depleted from topologically associated domain
- (TAD) boundaries (Li et al., 2020). However, in pediatric brain tumors, only large deletions

("Del2"), but not small deletions ("Del0" and "Del1"), were depleted from TAD boundaries(Figure 3).

227 Taking the above results together, our results suggest that the forming mechanisms of somatic

228 SVs, both complex and simple SVs, in pediatric brain tumors were likely to be different from

those of adult cancers.

Next, we sought to identify mutations associated with genome instability. As expected, TP53 230 231 mutations in HGGs were associated with "Chr bridge" and "Large loss", and cycle of templated 232 insertions, as well as six simple SV signatures: "Unbal inv", "Unbal tra", "Large mixed", "TD", 233 "Del1" and "Del2" (Figure S3). In addition, H3F3A mutations in HGGs were associated with 234 cycle of templated insertions (Figure S3) suggesting that histories may play important roles in genome instability in pediatric brain tumors. ATRX mutations in HGGs were associated with 235 "Large mixed" signatures (Figure S3). No other mutations were associated with any SV 236 237 signatures in any other pediatric brain tumors. In adult cancers, small deletions are associated with BRCA2 mutations, and small and large tandem duplications are associated with BRCA1 and 238 239 CDK12 mutations (Li et al., 2020; Nik-Zainal et al., 2016). In the 741 non-hypermutated pediatric brain tumors, only one sample carried a BRCA1 mutation, and another sample carried a 240 BRCA2 mutation. This again suggested that the mechanisms of formation of deletions and 241

tandem duplications in pediatric brain tumors are likely to be different from those of adultcancers.

244

#### 245 SV breakpoint sequences

246 We then investigated microhomology and insertion sequences at the SV breakpoints across SV 247 signatures. SVs are the results of erroneous repair of DNA double strand breaks or replication 248 errors. Various repair pathways are involved (Aguilera and García-Muse, 2013; Bunting and 249 Nussenzweig, 2013), such as non-homologous end joining (NHEJ), alternative end joining (alt-250 EJ), and microhomology-mediated break-induced repair (MMBIR). NHEJ usually ligates blunt DNA ends or ends with short 1-4bp homology. Alt-EJ often uses slightly longer homology for 251 252 repair. MMBIR is considered a replication based template switching mechanism and nontemplate insertions are frequently present at the breakpoints (Zhang et al., 2009). Several SV 253 signatures in pediatric brain tumors, including "Large loss", "Hourglass", chromoplexy, and 254 255 "Unbal tra", had a majority of SV breakpoints being blunt DNA ends (no homology nor insertion at the breakpoints) (Figure 4). This suggested that these SVs are likely to form through NHEJ. 256 Some other signatures, such as "Chr bridge", "Micronuclei", "Del0", "Del1", "Unbal inv", and 257 "Large mixed", had slightly longer homology at the breakpoints with 1bp microhomology being 258 the most frequent and also consistent with NHEJ (Figure 4). In addition, "TD", "Recip", and 259 "BRAF fusion" signatures had 2bp microhomology being the most frequent (Figure 4) suggesting 260 alt-EJ might play more important roles in these SVs. The observation of extended 261 microhomology in the "Recip" signature was consistent with breakpoints found in the 262 Philadelphia chromosome, the most prevalent reciprocal translocation in leukemia, often 263 involving 2-8 bp microhomology (McVey and Lee, 2008). Although previous studies proposed 264

that chromoplexy forms in a manner similar to reciprocal translocation (Baca et al., 2013; Berger

et al., 2011), our observation of chromoplexy and reciprocal translocation breakpoints with

267 different microhomology patterns suggested that they may form via different mechanisms.

Furthermore, a fraction of SVs in "Del1" had 5 bp or longer microhomology (Figure 4)

especially in ependymomas, suggesting alt-EJ being the dominant mechanism in ependymoma.

270 Intriguingly, "ecDNA" and "Large gain" signatures had frequent inserted sequences that were

271 more than 10 bp (Figure 4), suggesting possible involvement of replication-based mechanisms

- such as MMBIR.
- 273

#### 274 SV hotspots and tumor drivers

275 Hotspots of SV breakpoints often represent genetic alterations under positive selection and genes

driving diseases. After binning the reference genome into 1 Mb window and counting SV

277 occurrences, we found different SV signatures having quite distinct hotspots. *MYCN* and *MYC* 

are two frequently amplified oncogenes in pediatric brain tumors (Dubois et al., 2022).

279 Interestingly, *MYCN* was amplified exclusively by "ecDNA" in HGGs and exclusively by

280 "Large gain" in medulloblastomas (Figure 5), since "ecDNA" and "Large gain" were the most

abundant clustered complex SV signatures in HGGs and medulloblastomas, respectively. Both

signatures converged on *MYCN* amplifications, which are the main oncogenic events in HGGs

and medulloblastomas. *MYCN* was also amplified by non-clustered complex SV with unclear
 pattern ("Complex unclear") in various tumor types (Figure 5). Tandem duplications can also

amplify DNA. However, *MYCN* was not amplified by the "TD" signature in any samples,

whereas *MYC* was amplified by the "TD" signature in a few HGGs and medulloblastomas

287 (Figure 5). In addition, *FGFR1* was frequently amplified by the "TD" signature in DNETs

288 (Figure 5). DNETs had very few somatic SVs and did not carry any clustered or non-clustered

complex SVs. "TD" was the dominant SV signature in DNETs. These findings suggested that

290 "TD" and *FGFR1* amplifications were the major oncogenic events in DNETs. Furthermore,

chromoplexy and "Del2" frequently disrupted *CDKN2A* in various tumor types (Figure 5). The

292 "BRAF fusion" signature produced KIAA1549-BRAF fusions mainly in LGATs (Figure 5). The

293 "Recip" signature often led to *EWSR1* fusions in various tumor types (Figure 5).

Interestingly, multiple SV signatures harbored hotspots on chromosome 11, and the hotspots

were only found in ependymomas (Figure 5). *C11orf95-RELA* fusions are the major oncogenic

events in 70% of supratentorial ependymomas (Parker et al., 2014). Recently, the World Health

297 Organization (WHO) recommended the use of the *ZFTA* (*C110rf95*) fusion to classify

supratentorial ependymoma instead of the *RELA* fusion because *ZFTA* can fuse to other partners

as well (Louis et al., 2021). There were 71 ependymomas in our cohort and 23 of them (32%)

were supratentorial (Figure 6A and Table S4). Among them, 13 (57%) carried ZFTA fusions

301 (Figure 6A). There were 2 other *ZFTA* fusion positive ependymomas classified as "Others"

302 (Figure 6A). Twelve out of 15 *ZFTA* fusions were driven by complex SVs and three were driven

by tandem duplications ("TD") (Figure 6A). Among the 12 fusions resulting from complex

events, 5 were micronuclei-induced chromothripsis ("Micronuclei"), 3 were hourglass

chromothripsis ("Hourglass"), and 4 were non-clustered complex SVs (Figure 6A and 6B). Some

306 of the complex SVs involved the entire chromosome 11 (BS\_K6A9Z04J), whereas others only affected a small region in chromosome 11 (BS\_NWYBD9CA) (Figure 6B). These results 307 308 showed that there are diverse mechanisms generating genome instability in ependymomas and they have shared oncogenic consequence of forming ZFTA fusions. The most prevalent complex 309 SVs in ependymomas were micronuclei-induced chromothripsis events caused by erroneous 310 311 chromosomal segregation. It is possible that the frequent complex SVs in ependymomas are due

- to frequent chromosomal segregation errors. However, aneuploidy is rare in ependymomas 312
- (Mack and Taylor, 2017). This suggested that chromosomal segregation errors are likely not 313
- frequent events in ependymomas, and complex SVs in ependymomas are under positive 314
- 315 selection. Furthermore, since tandem duplications are sufficient to produce gene fusions, such as
- 316 ZFTA fusions and BRAF fusions, and the fact that most somatic SVs in ependymomas involving
- chromosome 11 were complex SVs suggested that other genes altered by SVs may contribute to 317
- ependymoma tumorigenesis as well. "Unbal inv" signature also had a hotspot in a similar region 318
- on chromosome 11 (Figure 5). Three ependymomas had unbalanced inversions in gene MARK2, 319
- which is next to ZFTA, and no fusions were formed. Whether this "Unbal inv" hotspot in 320
- ependymoma reflects oncogenic events remains unclear. 321
- In a significant fraction of pediatric brain tumors, the disease-causing SVs were the sole SVs of 322
- the corresponding signatures. These signatures did not produce additional passenger SVs in those 323
- samples. For example, 88 LGATs were driven by BRAF fusions and there was only one SV 324
- within the "BRAF fusion" signature in those samples (Figure 2B). Similarly, three ependymomas 325
- 326 carried ZFTA fusions caused by the "TD" signature, and there was only one SV within the "TD"
- signature in two of these three samples (Figure 2B and Figure 5). In addition, nine DNETs had 327
- FGFR1 amplifications resulting from the "TD" signature, and there was only one SV within the 328
- 329 "TD" signature in all nine samples (Figure 2B and Figure 5). These results indicated that the
- molecular mechanisms leading to these disease-driving SVs are not highly active in tumor 330
- initiating cells. Cells independently acquire SVs through these mechanisms at very low rates, and 331 cells that have acquired SVs that alter the major disease-driving genes eventually outcompete
- 332
- 333 other cells and become tumors.
- 334

#### Impact of SVs on patient survival 335

Next, we sought to evaluate whether somatic SVs affect patient survival in pediatric brain 336

- tumors. Chromothripsis has been associated with worse patient survival in several previous 337
- studies (Cortés-Ciriano et al., 2020; Molenaar et al., 2012; Notta et al., 2016; Rausch et al., 338
- 2012b). However, we did not observe any complex SV signatures associated with patient 339
- survival in HGGs, LGATs, medulloblastomas or ependymomas (Figure S4). HGG patients with 340
- 341 "Del2" and "Unbal tra" signatures in their tumors had significantly worse survival, and those
- with "Del1" and "Large mixed" signatures had marginally worse survival (Figure 7). HGGs were 342
- most abundant in simple SVs, which suggested that the SV forming mechanisms are relatively 343
- more active in tumor initiating cells of HGGs than those of other tumor types. No simple SV 344
- signatures were associated with patient survival in other tumor types. It is possible that simple 345

- 346 SV forming mechanisms are not very active in tumor types other than HGGs; therefore simple
- 347 SV signatures are associated with patient survival only in HGGs.

348

# 349 Acknowledgement

- 350 We thank the Center for Research Informatics at the University of Chicago for providing the
- 351 computing infrastructure. We thank Dr. Ji Won Lee for assistance in tumor pathology. The work
- 352 was supported by the National Institutes of Health grant R03CA246228 (L.Y.).

#### 353 Author contributions

- L.Y. conceptualized the study. Y.Y. developed the analysis workflow and performed the
- analysis. Y.Y. and L.Y. interpreted the results. L.Y. supervised the study. L.Y. wrote the paper.
- 356 All authors have read and approved the final manuscript.

357

# 358 **Declaration of interests**

359 The authors have no competing interests to declare.

360

#### 361 Figure Legends

Figure 1 Somatic SVs and complex SVs in 744 pediatric brain tumors. (A) Frequencies of 362 somatic SVs and percentages of different types of SVs. In the upper panel, each dot represents 363 364 one pediatric brain tumor sample. Samples are grouped by tumor type and tumor types are sorted by median SV frequency (red lines) except for the "Others" category. The numbers in 365 366 parentheses are sample sizes for the corresponding tumor types. The bottom panel shows the percentages of clustered complex SVs, non-clustered complex SVs, and simple SVs in the 367 368 corresponding samples on the top panel. HGG: high-grade glioma. ATRT: atypical teratoid/rhabdoid tumor. LGAT: low-grade astrocytic tumor. DNET: dysembryoplastic 369 neuroepithelial tumor. (B) and (D) Percentages of clustered complex SV signatures and non-370 371 clustered complex SVs. Each vertical block represents one tumor type and each horizontal bar represent one sample. Samples are colored based on their SV signatures. Samples carry multiple 372 373 signatures have multiple colors arranged horizontally. The height of each sample may differ across tumor types depending on sample sizes of the tumor types. (C) Examples of clustered 374 375 complex SVs. Colored arcs represent SVs of different types. The red bars below the SVs indicate regions of clustered complex SVs. Copy number profiles are displayed by black bars above the 376 chromosome models. The red bars within the grey chromosome models indicate the locations of 377 centromeres. Tumor types and sample IDs are shown next to the names of clustered complex SV 378 signatures. DEL: deletion, DUP: tandem duplication, h2hINV: head to head inversion, t2tINV: 379

tail to tail inversion, TRA: translocation.

Figure 2 Simple SV signatures and their distributions. (A) Nine simple SV signatures of 744 381 pediatric brain tumors. The four major SV categories and 49 subcategories of simple SVs are 382 shown on the y axis. The names of the nine simple SV signatures are displayed on the top. The 383 relative contributions of SV subcategories to the corresponding signatures are shown on the x 384 385 axis. (B) Frequencies of simple SVs and percentages of simple SV signatures. In the upper panel, each dot represents one sample. Samples are grouped by tumor types. Red bars indicate median 386 387 frequencies. The numbers in parentheses are sample sizes for the corresponding tumor types. The bottom panel shows the percentages of simple SV signatures in the corresponding samples on the 388 top panel. 389

Figure 3 Associations of SV signatures with 31 genomic features. SV signatures and genomic 390 391 features are listed in the x and y axes respectively. Each dot represents the association between one SV signature and one genomic feature. The bigger the dots are, the more significant the 392 associations are. The colors of the dots indicate the directions of median shift. The directions of 393 biases are shown in the parentheses of genomic features. For instance, the "ecDNA" signature 394 has red color (left on the color key) dot for centromere, indicating that the observed SV 395 breakpoints of this signature are farther away (left in the parentheses) from centromeres than 396 397 randomized breakpoints.

Figure 4 SV breakpoint homology. The distributions (x axis) of homology and insertion at SV breakpoints are shown for all SV signatures (y axis). The putative DNA repair mechanisms are inferred from the sizes of homology and insertion and annotated next to the signatures. The bars indicate number of somatic SVs and are colored by tumor type. MMBIR: microhomology-

- 402 mediated break-induced repair. NHEJ: non-homologous end joining. alt-EJ: alternative end403 joining.
- 404 Figure 5 SV breakpoint hotspots. SV breakpoint frequencies are shown for the entire reference
- 405 genome (x axis) across different SV signatures (y axis). Chromosome models are shown as grey
- 406 bars with red lines indicating locations of centromeres at the bottom. Hotspots containing known
- 407 oncogenes, tumor suppressors, and fragile sites are annotated.
- 408 **Figure 6** *ZFTA* **fusions in ependymomas.** (A) The prevalence of *ZFTA* fusions in 71
- 409 ependymomas. Samples are colored by signatures of the SVs resulting in ZFTA fusions and
- 410 ependymoma subtypes. (B) Six examples of ZFTA fusions resulting from different SV
- signatures. SV signatures and sample IDs are shown on the top. Somatic SVs, regions of
- 412 complex SVs and copy number profiles are displayed in the same scheme as Figure 1C. The
- 413 *ZFTA* and *RELA* regions are zoomed in and *ZFTA* gene and *RELA* gene are further zoomed in
- respectively. Gene structures are shown at the bottom of six examples. Within gene structures,
- the SV breakpoints that lead to *ZFTA-RELA* fusions are shown as red vertical lines. The
- 416 directions of gene transcription are indicated by arrows.
- 417 Figure 7 SV signatures associated with patient survival. Kaplan-Meier survival curves for
- 418 HGG patients, stratified by the presence or absence of four simple SV signatures ("Del2",
- 419 "Unbal tra", "Del1", and "Large mixed") are shown. P values are calculated by log-rank test.

#### 420 STAR Methods

#### 421 Sample and data collection

- 422 The raw normal and tumor whole-genome sequencing data for 744 pediatric brain tumor patients
- 423 were downloaded from CAVATICA (<u>https://cavatica.sbgenomics.com/</u>). Sample characteristics,
- 424 clinical data, somatic SNV, and somatic CNV data were retrieved from OpenPBTA GitHub
- 425 (https://github.com/AlexsLemonade/OpenPBTA-analysis,
- 426 <u>https://www.biorxiv.org/content/10.1101/2022.09.13.507832v1</u>). All patients were de-identified.
- 427 Gene annotation was obtained from ENSEMBL (GRCh38.p13)
- 428 (https://useast.ensembl.org/index.html). Non-B DNA structures including A-phased repeats,
- direct repeats, G-quadruplex forming repeats, inverted repeats, mirror repeats, short tandem
- 430 repeats and Z-DNA motifs were downloaded from non-B DB (Cer et al., 2013) (https://nonb-
- 431 <u>abcc.ncifcrf.gov/apps/nBMST/default/</u>); Alu, L1, L2, LTR, MIR, simple repeat, transposon, and
- low complexity repetitive elements, as well as the coordinates of centromeres, telomeres, and
- 433 CpG islands, were obtained from UCSC
- 434 (<u>https://hgdownload.soe.ucsc.edu/goldenPath/hg38/database/</u>); consensus estimate of the
- topologically associated domains (TADs) were downloaded from TAD Map (Singh and Berger,
- 436 2021) (https://cb.csail.mit.edu/cb/tadmap/); ChIP-seq data of epigenetic markers H3K4me1,
- 437 H3K9me3, H3K36me3, H3K4me3, H3K27me3, H3K9ac, H3K4me2, H3K79me2, H3K27ac,
- and H4K20me1 from human astrocyte were downloaded from ENCODE (Zhang et al., 2020)
- 439 (<u>https://www.encodeproject.org/</u>). The Wavelet-smoothed signal of replication timing data for
- the cell lines BG02ES and SK-N-SH were downloaded from UCSC
- 441 (<u>https://genome.ucsc.edu/cgi-bin/hgFileUi?db=hg19&g=wgEncodeUwRepliSeq</u>). The fragile
- site regions were obtained from a previous study (Li et al., 2020), and the coordinates were lifted
- over to hg38. All coordinates in this study were based on the hg38 genome assembly unless
- 444 otherwise noted.

# 445 **Tumor classifications**

- 446 The histological classifications of tumor samples were determined based on diagnosis,
- 447 pathological examination, and histological examination according to the 2021 WHO
- classifications of pediatric brain tumors (Louis et al., 2021). For tumor types with at least 10
- samples, we attempted to subclassify them. Gliomas were subclassified into high-grade gliomas
- 450 (HGGs), low-grade astrocytic tumors (LGATs), ependymomas, dysembryoplastic neuroepithelial
- 451 tumors (DNETs), and gangliogliomas. Embryonal tumors were subclassified into
- 452 medulloblastomas, and atypical teratoid rhabdoid tumors (ATRTs). Cranial and paraspinal nerve
- 453 tumors included schwannomas and neurofibromas. Germ cell tumors included teratomas,
- 454 germinomas, and other germ cell tumors. Mesenchymal non-meningothelial tumors included
- 455 hemangioblastomas, Ewing sarcomas, rhabdomyosarcomas, myofibroblastomas, and other
- 456 sarcomas. Meningiomas, craniopharyngiomas, and choroid plexus tumors were independently
- 457 classified. Tumor types with less than 10 samples were all classified into "Others".
- 458 Ependymomas were further stratified into distinct subtypes based on the primary sites.
- 459 Somatic SV calling and filtering

- 460 Manta (<u>https://github.com/Illumina/manta</u>), Meerkat (<u>https://github.com/guru-yang/Meerkat</u>),
- and Delly (<u>https://github.com/dellytools/delly</u>) were used for somatic SV detection. SVs called
- by Manta were obtained from OpenPBTA. Meerkat was run as suggested (Yang et al., 2013).
- 463 Delly was run with default settings. For SVs detected by Delly, at least four supporting read pairs
- and split read combined were required for SVs less than 500 bp. For all three SV detection
- algorithms, only SVs located in canonical chromosomes (chr1-22, X, Y) were retained. SVs
- identified by different algorithms were considered identical if their two breakpoints were on the
- same chromosomes, with the same orientations and within 10 bp. SVs identified by two or more
- 468 algorithms were considered high-confidence SVs and used in the subsequent analysis. Deletions
- 469 with both breakpoints within 3 bp of exon-intron boundaries of the same genes were excluded
- 470 from further analysis.
- 471 Somatic CNVs were used to assess the quality of somatic SVs. For each SV, if the distances of
- both SV breakpoints were less than 1 kb to the nearest CNV breakpoints, the SV was considered
- 473 validated.

# 474 **Complex SVs and their signatures**

- 475 We used Starfish (Bao et al., 2022) (<u>https://github.com/yanglab-computationalgenomics/Starfish</u>)
- to detect clustered complex SVs and classified them into six signatures. In cases where reported
- 477 gender and germline estimated sex were inconsistent, gender identity was recorded as unknown
- 478 for signature detection. After removing clustered complex SVs, we used ClusterSV (Li et al.,
- 479 2020) (https://github.com/cancerit/ClusterSV) to identify non-clustered complex SVs. Non-
- 480 clustered complex SVs include chromoplexy, cycle of templated insertions, and complex
- 481 unclear.

# 482 Simple SV signatures

- 483 After removing clustered and non-clustered complex SVs, the remainder were simple SVs
- 484 including four major categories: deletions, tandem duplications, inversions, and translocations.
- 485 Deletions and tandem duplications with breakpoints falling within fragile site regions were
- 486 classified as fragile site deletions and fragile site tandem duplications, respectively. The
- remaining deletions and tandem duplications were classified into 18 subcategories based on their
- 488 sizes. Inversions and translocations were further subclassified into reciprocal inversions, fold-
- back inversions, unbalanced inversions, reciprocal translocations, and unbalanced translocations.
- 490 Unbalanced inversions and reciprocal inversions were classified into 3 and 5 subcategories based
- 491 on their sizes, respectively. Fold-back inversions, unbalanced translocations, and reciprocal
- translocations were three independent subcategories. As a result, all simple SVs were classified
- into 49 subcategories and SigProfilerExtractor (Islam et al., 2022)
- 494 (<u>https://github.com/AlexandrovLab/SigProfilerExtractor</u>) with default parameters was used to
- 495 extract simple SV signatures. According to the final signatures we chose, deletions smaller than
- 1kb were assigned as "Del0"; deletions ranging in size from 1kb-5kb were classified as "Del1";
- 497 fragile site deletions, fragile site tandem duplications, and deletions sized in 5kb-10Mb were
- assigned as "Del2"; tandem duplications between 1Mb-2.5Mb with breakpoints located within
- 499 the *BRAF* region were classified as *BRAF* fusion signature; other tandem duplications were

classified as "TD"; foldback inversions and unbalanced inversions sized between 50kb-5Mb

501 were categorized as "Unbal inv"; deletions and tandem duplications larger than 10Mb, as well as

reciprocal unbalanced inversions larger than 5Mb, were classified as "Large mixed"; reciprocal

- 503 inversions and reciprocal translocations were categorized as "Recip"; and unbalanced
- translocations were classified as "Unbal tra".

#### 505 Genomic feature tests

- 506 For each observed somatic SV, we generated four random SVs on the same chromosome, same
- size, and same type. All observed and randomized breakpoints were annotated with genomic
- features. Bedtools was used to compute the GC content within a  $\pm 50$  bp interval of each SV
- 509 breakpoint. The distances in kilobases (kb) from the breakpoints to the nearest Non-B DNA
- structures, repetitive elements, and CpG islands were logarithmically transformed, with the
- distances set to 0 if breakpoints were within any of the aforementioned elements. The distances
- in megabases (Mb) from the breakpoints to centromeres and telomeres and the distances (kb) to
- the closest TAD boundaries were also transformed to log scale. The SV breakpoints were
- annotated by signal -log10(p-values) for different epigenetic modifications. The replication
- timing data for cell lines BG02ES and SK-N-SH were quantile normalized. The SV breakpoints
- were lifted over to hg19 since the replication timing data were based on hg19. The replication
- timing values were then annotated for each SV breakpoint. Breakpoints of observed SVs and
- randomized SVs were tested as described in the previous study (Li et al., 2020). Briefly, scores
- of SV breakpoints for all genomic features were rescaled from 0 to 1. The distributions of scores
- 520 between observed breakpoints and randomized breakpoints were compared using two-sided
- 521 Kolmogorov-Smirnov test. False discovery rates (FDRs) were computed using the Benjamini-
- 522 Hochberg procedure and 0.1 FDR cutoff was used to determine significant associations.
- 523 Homology and insertion size at the SV breakpoints were provided by Meerkat and Manta.

# 524 Hotspot analysis

- 525 The reference genome was divided into 1Mb non-overlapping bins. The number of samples with
- 526 SV breakpoints in each bin was counted for each SV signature. A sample with multiple SV
- 527 breakpoints of the same SV signatures falling within the same bin was only counted once.

# 528 Mutation test

- 529 Only protein-altering somatic SNVs and indels were considered, including missense mutations,
- splice site mutations, frameshift indels, nonsense mutations, translation start site mutations, and
- nonstop mutations. Three HGG samples (BS\_20TBZG09, BS\_02YBZSBY, and
- 532 BS\_VW4XN9Y7) with hypermutation were excluded. The tests were performed within tumor
- types. Protein-coding genes with mutation frequencies >= 5% in each tumor type were analyzed.
- 534 Samples were classified into two categories based on the presence and absence of the SV
- signatures. Fisher's exact test was used to calculate p values. FDRs were computed using the
- 536 Benjamini-Hochberg procedure. FDR < 0.1 was considered as significant.

# 537 Survival analysis

- 538 Since patient survival differs dramatically across tumor types, survival analysis was only
- performed within tumor types, but not across tumor types. For clustered complex SV signatures,
- samples with only one signature were assigned to the corresponding signatures; samples with
- 541 more than one clustered complex SV signatures were classified into "Mixed"; and samples
- 542 without any clustered complex SV were assigned into "None". For simple SV signatures,
- samples were classified based on the presence and absence of the signatures. Log-rank test was
- 544 used to calculate p values.

#### 545 **References**

- Aguilera, A., and García-Muse, T. (2013). Causes of genome instability. Annu. Rev. Genet. 47,
  1–32.
- 548 Akdemir, K.C., Le, V.T., Chandran, S., Li, Y., Verhaak, R.G., Beroukhim, R., Campbell, P.J.,
- 549 Chin, L., Dixon, J.R., Futreal, P.A., et al. (2020). Disruption of chromatin folding domains by 550 somatic genomic rearrangements in human cancer. Nat. Genet. *52*, 294–305.
- 551 Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A.J.R., Behjati, S., Biankin, A. V.,
- 552 Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A.-L., et al. (2013). Signatures of mutational
- processes in human cancer. Nature 500, 415–421.
- Alexandrov, L.B., Kim, J., Haradhvala, N.J., Huang, M.N., Tian Ng, A.W., Wu, Y., Boot, A.,
- 555 Covington, K.R., Gordenin, D.A., Bergstrom, E.N., et al. (2020). The repertoire of mutational 556 signatures in human cancer. Nature *578*, 94–101.
- Alt, F.W., Zhang, Y., Meng, F.L., Guo, C., and Schwer, B. (2013). Mechanisms of programmed
  DNA lesions and genomic instability in the immune system. Cell *152*, 417–429.
- 559 Baca, S.C., Prandi, D., Lawrence, M.S., Mosquera, J.M., Romanel, A., Drier, Y., Park, K.,
- 560 Kitabayashi, N., MacDonald, T.Y., and Ghandi, M. (2013). Punctuated evolution of prostate
- cancer genomes. Cell *153*, 666–677.
- 562 Bakhshi, A., Jensen, J.P., Goldman, P., Wright, J.J., McBride, O.W., Epstein, A.L., and
- Korsmeyer, S.J. (1985). Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18. Cell *41*, 899–906.
- Bao, L., Zhong, X., Yang, Y., and Yang, L. (2022). Starfish infers signatures of complex
  genomic rearrangements across human cancers. Nat. Cancer 2022 310 *3*, 1247–1259.
- 567 Berger, M.F., Lawrence, M.S., Demichelis, F., Drier, Y., Cibulskis, K., Sivachenko, A.Y.,
- 568 Sboner, A., Esgueva, R., Pflueger, D., Sougnez, C., et al. (2011). The genomic complexity of
- 569 primary human prostate cancer. Nature 470, 214–220.
- Bunting, S.F., and Nussenzweig, A. (2013). End-joining, translocations and cancer. Nat. Rev.
  Cancer *13*, 443–454.
- 572 Campbell, P.J., Getz, G., Korbel, J.O., Stuart, J.M., Jennings, J.L., Stein, L.D., Perry, M.D.,
- 573 Nahal-Bose, H.K., Ouellette, B.F.F., Li, C.H., et al. (2020). Pan-cancer analysis of whole 574 genomes. Nature *578*, 82–93.
- 575 Cer, R.Z., Donohue, D.E., Mudunuri, U.S., Temiz, N.A., Loss, M.A., Starner, N.J., Halusa, G.N.,
- 576 Volfovsky, N., Yi, M., Luke, B.T., et al. (2013). Non-B DB v2.0: a database of predicted non-B
- 577 DNA-forming motifs and its associated tools. Nucleic Acids Res. 41.
- 578 Chen, X., Schulz-Trieglaff, O., Shaw, R., Barnes, B., Schlesinger, F., Källberg, M., Cox, A.J.,
- 579 Kruglyak, S., and Saunders, C.T. (2016). Manta: rapid detection of structural variants and indels 580 for germline and cancer sequencing applications. Bioinformatics *32*, 1220–1222.
- 581 Cortés-Ciriano, I., Lee, J.J.-K., Xi, R., Jain, D., Jung, Y.L., Yang, L., Gordenin, D., Klimczak,
- L.J., Zhang, C.-Z., Pellman, D.S., et al. (2020). Comprehensive analysis of chromothripsis in

- 583 2,658 human cancers using whole-genome sequencing. Nat. Genet. 52, 331–341.
- 584 Degasperi, A., Zou, X., Amarante, T.D., Martinez-Martinez, A., Koh, G.C.C., Dias, J.M.L.,
- Heskin, L., Chmelova, L., Rinaldi, G., Wang, V.Y.W., et al. (2022). Substitution mutational
- signatures in whole-genome–sequenced cancers in the UK population. Science *376*.
- 587 Drews, R.M., Hernando, B., Tarabichi, M., Haase, K., Lesluyes, T., Smith, P.S., Morrill Gavarró,
- 588 L., Couturier, D.L., Liu, L., Schneider, M., et al. (2022). A pan-cancer compendium of
- chromosomal instability. Nature *606*, 976–983.
- 590 Dubois, F.P.B., Shapira, O., Greenwald, N.F., Zack, T., Wala, J., Tsai, J.W., Crane, A., Baguette,
- A., Hadjadj, D., Harutyunyan, A.S., et al. (2022). Structural variants shape driver combinations
  and outcomes in pediatric high-grade glioma. Nat. Cancer 2022 38 *3*, 994–1011.
- Farmer, H., McCabe, H., Lord, C.J., Tutt, A.H.J., Johnson, D.A., Richardson, T.B., Santarosa,
  M., Dillon, K.J., Hickson, I., Knights, C., et al. (2005). Targeting the DNA repair defect in
- 595 BRCA mutant cells as a therapeutic strategy. Nature 434, 917–921.
- 596 Fong, P.C., Boss, D.S., Yap, T.A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P.,
- 597 Swaisland, H., Lau, A., O'Connor, M.J., et al. (2009). Inhibition of Poly(ADP-Ribose)
- 598 Polymerase in Tumors from BRCA Mutation Carriers. N. Engl. J. Med. *361*, 123–134.
- 599 Gostissa, M., Yan, C.T., Bianco, J.M., Cogné, M., Pinaud, E., and Alt, F.W. (2009). Long-range
- oncogenic activation of Igh-c-myc translocations by the Igh 3' regulatory region. Nature 462,
  803–807.
- 602 Gröbner, S.N., Worst, B.C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V.A.,
- Johann, P.D., Balasubramanian, G.P., Segura-Wang, M., Brabetz, S., et al. (2018). The landscape
   of genomic alterations across childhood cancers. Nature 555, 321–327.
- Hakim, O., Resch, W., Yamane, A., Klein, I., Kieffer-Kwon, K.R., Jankovic, M., Oliveira, T.,
- Bothmer, A., Voss, T.C., Ansarah-Sobrinho, C., et al. (2012). DNA damage defines sites of
- recurrent chromosomal translocations in B lymphocytes. Nature 484, 69–74.
- Islam, S.M.A., Díaz-Gay, M., Wu, Y., Barnes, M., Vangara, R., Bergstrom, E.N., He, Y., Vella,
- M., Wang, J., Teague, J.W., et al. (2022). Uncovering novel mutational signatures by de novo
  extraction with SigProfilerExtractor. Cell Genomics 0, 100179.
- Lee, J.-K., Choi, Y.-L., Kwon, M., and Park, P.J. (2016). Mechanisms and Consequences of
- 612 Cancer Genome Instability: Lessons from Genome Sequencing Studies. Annu. Rev. Pathol.
- 613 Mech. Dis. 11, 283–312.
- Li, Y., Roberts, N.D., Wala, J.A., Shapira, O., Schumacher, S.E., Kumar, K., Khurana, E.,
- Waszak, S., Korbel, J.O., Haber, J.E., et al. (2020). Patterns of somatic structural variation in
  human cancer genomes. Nature *578*, 112–121.
- Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., Scheithauer,
- B.W., and Kleihues, P. (2007). The 2007 WHO classification of tumours of the central nervous
  system. Acta Neuropathol. *114*, 97–109.
- Louis, D.N., Perry, A., Wesseling, P., Brat, D.J., Cree, I.A., Figarella-Branger, D., Hawkins, C.,
- Ng, H.K., Pfister, S.M., Reifenberger, G., et al. (2021). The 2021 WHO Classification of Tumors

- of the Central Nervous System: a summary. Neuro. Oncol. 23, 1231–1251.
- 623 Maciejowski, J., Li, Y., Bosco, N., Campbell, P.J., and de Lange, T. (2015). Chromothripsis and
- Kataegis Induced by Telomere Crisis. Cell *163*, 1641–1654.
- Mack, S.C., and Taylor, M.D. (2017). Put away your microscopes: The ependymoma molecular era has begun. Curr. Opin. Oncol. *29*, 443.
- 627 McVey, M., and Lee, S.E. (2008). MMEJ repair of double-strand breaks (director's cut): deleted
- sequences and alternative endings. Trends Genet. 24, 529–538.
- Molenaar, J.J., Koster, J., Zwijnenburg, D.A., van Sluis, P., Valentijn, L.J., van der Ploeg, I.,
- Hamdi, M., van Nes, J., Westerman, B.A., van Arkel, J., et al. (2012). Sequencing of
- neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature 483, 589–
   593.
- Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I.,
- Alexandrov, L.B., Martin, S., Wedge, D.C., et al. (2016). Landscape of somatic mutations in 560
   breast cancer whole-genome sequences. Nature 534, 47–54.
- Notta, F., Chan-Seng-Yue, M., Lemire, M., Li, Y., Wilson, G.W., Connor, A.A., Denroche, R.E.,
- Liang, S.-B., Brown, A.M.K., Kim, J.C., et al. (2016). A renewed model of pancreatic cancer
- evolution based on genomic rearrangement patterns. Nature *538*, 378–382.
- Ostrom, Q.T., de Blank, P.M., Kruchko, C., Petersen, C.M., Liao, P., Finlay, J.L., Stearns, D.S.,
- Wolff, J.E., Wolinsky, Y., Letterio, J.J., et al. (2015). Alex's Lemonade Stand Foundation Infant
   and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United
- 641 and Childhood Filliary Drain and Central Netvous System Fullions Diagnosed in the Onited
- 642 States in 2007–2011. Neuro. Oncol. *16*, x1–x36.
- Parker, M., Mohankumar, K.M., Punchihewa, C., Weinlich, R., Dalton, J.D., Li, Y., Lee, R.,
- Tatevossian, R.G., Phoenix, T.N., Thiruvenkatam, R., et al. (2014). C11orf95–RELA fusions
- drive oncogenic NF- $\kappa$ B signalling in ependymoma. Nature 506, 451–455.
- Rausch, T., Zichner, T., Schlattl, A., Stütz, A.M., Benes, V., and Korbel, J.O. (2012a). DELLY:
  structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28,
  i333–i339.
- Rausch, T., Jones, D.T.W., Zapatka, M., Stütz, A.M., Zichner, T., Weischenfeldt, J., Jäger, N.,
- 650 Remke, M., Shih, D., Northcott, P.A., et al. (2012b). Genome sequencing of pediatric
- medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148, 59–71.
- 652 Shoshani, O., Brunner, S.F., Yaeger, R., Ly, P., Nechemia-Arbely, Y., Kim, D.H., Fang, R.,
- 653 Castillon, G.A., Yu, M., Li, J.S.Z., et al. (2020). Chromothripsis drives the evolution of gene
- amplification in cancer. Nature *591*, 137–141.
- Singh, R., and Berger, B. (2021). Deciphering the species-level structure of topologically
  associating domains. BioRxiv 2021.10.28.466333.
- 657 Steele, C.D., Abbasi, A., Islam, S.M.A., Bowes, A.L., Khandekar, A., Haase, K., Hames-Fathi,
- 658 S., Ajayi, D., Verfaillie, A., Dhami, P., et al. (2022). Signatures of copy number alterations in
- human cancer. Nature *606*, 984–991.

- 660 Stephens, P.J., Greenman, C.D., Fu, B., Yang, F., Bignell, G.R., Mudie, L.J., Pleasance, E.D.,
- Lau, K.W., Beare, D., Stebbings, L.A., et al. (2011). Massive genomic rearrangement acquired in
- a single catastrophic event during cancer development. Cell *144*, 27–40.
- 463 Yang, L., Luquette, L.J., Gehlenborg, N., Xi, R., Haseley, P.S., Hsieh, C.-H., Zhang, C., Ren, X.,
- 664 Protopopov, A., Chin, L., et al. (2013). Diverse mechanisms of somatic structural variations in
- human cancer genomes. Cell *153*, 919–929.
- Zhang, C.-Z., Spektor, A., Cornils, H., Francis, J.M., Jackson, E.K., Liu, S., Meyerson, M., and
  Pellman, D. (2015). Chromothripsis from DNA damage in micronuclei. Nature *522*, 179–184.
- <sup>668</sup> Zhang, F., Khajavi, M., Connolly, A.M., Towne, C.F., Batish, S.D., and Lupski, J.R. (2009). The
- 669DNA replication FoSTeS/MMBIR mechanism can generate genomic, genic and exonic complex
- 670 rearrangements in humans. Nat. Genet. 41, 849–853.
- Zhang, J., Lee, D., Dhiman, V., Jiang, P., Xu, J., McGillivray, P., Yang, H., Liu, J., Meyerson,
- W., Clarke, D., et al. (2020). An integrative ENCODE resource for cancer genomics. Nat.Commun. *11*.
- 075 Commun. 11.
- Zhang, Y., Chen, F., Donehower, L.A., Scheurer, M.E., and Creighton, C.J. (2021). A pediatric
- brain tumor atlas of genes deregulated by somatic genomic rearrangement. Nat. Commun. *12*,
- 676 937.

677



3

2

1 -



chr11





			Clustered complex SV signatures					No cor	n-clus nplex	tered SVs	Simple SV signatures								
		1 ecDNA	2 Chr bridge	3 Large loss	4 Micronuclei	<mark>5 Large gain</mark>	6 Hourglass	Chromoplexy	Cycle of templated ins	Cplx unclear	Del0	Del1	Del2	TD	Unbal inv	Large mixed	Recip	Unbal tra	BRAF fusion
	Replication timing (early-late)																		
	GC content (low-high)						$\bigcirc$		•	•							$\bigcirc$		
	CpG island (far-near)								•										
	Centromere (far-near)					$\bigcirc$	$\bigcirc$	$\bigcirc$				$\bigcirc$	$\bigcirc$					•	
	Telomere (far-near)		$\bigcirc$											0		0		•	
	Alu (far-near)			۰		0	$\bigcirc$	0	•				0	0	0	0	•		
	L1 (far-near)	$\bigcirc$		۰		0	$\bigcirc$		٠				0		0	0	٠		
	L2 (far-near)			۰	0	0	0	$\bigcirc$	•				0	0		•			
	LTR (far-near)	$\bigcirc$	$\bigcirc$	$\bigcirc$				$\bigcirc$									*		$\bigcirc$
	MIR (far-near)		$\bigcirc$								•					*		•	•
	Simple repeat (far-near)	•	$\bigcirc$						•									•	
	DNA transposon (far-near)	$\bigcirc$	$\bigcirc$		$\bigcirc$				•	$\bigcirc$								•	$\bigcirc$
	Low complexity (far-near)	•	$\bigcirc$		•		$\bigcirc$	$\bigcirc$								•			$\bigcirc$
	A-phased repeat (far-near)	•					$\bigcirc$			$\bigcirc$				$\bigcirc$		•		•	$\bigcirc$
	Direct repeat (far-near)	$\bigcirc$	$\bigcirc$		$\bigcirc$	0	0			*			0					•	•
	G-quadruplex motif (far-near)									$\bigcirc$						0	*		
	Inverted Repeat (far-near)	•			0		0	٠	٠	•	•	•					•	•	
	Mirror repeat (far-near)	•	•	٠		•			•	•	•					*	*	•	$\bigcirc$
	Short tandem repeat (far-near)	•	•	•	$\bigcirc$	٠	٠		•	•	•	•	*	*	٠	+		•	•
	z-DNA (far-near)		•	*					•	•			*				•	•	
	H3K4me1 (low-high)		•	•					•	$\bigcirc$	•		٠			٠	•	•	$\bigcirc$
	H3K4me2 (low-high)	$\bigcirc$	$\bigcirc$	٠			0		•	$\bigcirc$	•	•	0		۰	٠	•	•	
	H3K4me3 (low-high)	$\bigcirc$		٠			$\bigcirc$	$\bigcirc$	٠	•	•		0			۰	•	•	
	H3K9ac (low-high)	٠	$\bigcirc$	٠		•			۰	$\bigcirc$	•		0	$\bigcirc$		•	۰	٠	
	H3K9me3 (low-high)		$\bigcirc$	٠	0		0	$\bigcirc$	٠	•	•		$\bigcirc$	0	0		•	٠	
	H3K27ac (low-high)	$\bigcirc$	*					٠	•	*							*	•	
	H3K27me3 (low-high)	٠	$\bigcirc$		$\bigcirc$		$\bigcirc$	$\bigcirc$	•	*					٠			٠	
	H3K36me3 (low-high)	٠	•	•	$\bigcirc$	$\bigcirc$	$\bigcirc$		•	•	•				٠		•	٠	
	H3K79me2 (low-high)	$\bigcirc$	•	•			$\bigcirc$		•	$\bigcirc$	•		$\bigcirc$		•		•	•	
	H4K20me1 (low-high)		•	٠					•		•		$\bigcirc$	$\bigcirc$			•	•	•
Jai 11 za	TAD (far-near)	$\bigcirc$	٠	$\bigcirc$					۰	$\bigcirc$	٠	۰		0	0	0	۰		
5			Media	an shift	-0.5	(	0.0	0.5		FDR	• Not	signifi	cant	• 0.1		1e-3	•1	e-6	

Basic sequence features

Repeats

Non-B DNA

Histone markers

Genome organization









